Latin America Blood Glucose Monitor Market

The regional market is growing due to the increasing incidence of diabetes. This disease prevalence is influenced by the rising number of obese individuals, lifestyle-related risk factors, and the presence of a substantial number of undiagnosed diabetics. Increasing recognition of the significance of early diagnosis and proper management of the disease, especially in Brazil, Mexico, Argentina, and Colombia, boosts the demand for self-monitoring of blood glucose (SMBG) and, to a lesser extent, continuous glucose monitoring (CGM) systems. Improvements in the availability of healthcare services, better access to private healthcare facilities, and public health initiatives aimed at improving diabetes care are also contributing to the availability of glucose monitoring solutions through hospital and retail pharmacy chains. Physicians’ interest in reliable and easily accessible monitoring solutions, especially for high-risk and insulin-dependent patients, also drives the market.

Prominent players in the Latin America blood glucose monitor market include Abbott Laboratories (US), Medtronic (Ireland), F. Hoffmann-La Roche Ltd. (Switzerland), DexCom, Inc. (US), Arkray, Inc. (Japan), and Ascensia Diabetes Care Holdings AG (Switzerland). These companies leverage growth strategies, such as partnerships, expansions, and collaborations, to increase product offerings and reinforce their presence.

To know about the assumptions considered for the study download the pdf brochure

For instance, in November 2024, DexCom, Inc. (US) announced a strategic partnership with smart-ring company OURA, enabling two-way integration between DexCom glucose biosensors and the OURA Ring and app, enriching users’ metabolic health insights by combining glucose data with vital signs, sleep, stress, and activity metrics. As part of the collaboration, DexCom has also invested USD 75 million in OURA’s Series D funding round.

Abbott Laboratories (US)

Abbott Laboratories is a healthcare leader operating in over 160 countries. Through its Medical Devices division, the company has built a strong presence in diabetes care, offering continuous and traditional blood glucose monitoring solutions under the FreeStyle brand. Its flagship FreeStyle Libre system, comprising sensors, test strips, data management software, and related accessories, has revolutionized glucose tracking by providing real-time insights for better diabetes management. Additionally, the launch of the Lingo continuous glucose monitoring system for broader health and wellness applications has further strengthened Abbott’s position as an innovation leader in the blood glucose monitor market.

DexCom, Inc. (US)

DexCom, Inc. develops, manufactures, and commercializes real-time CGM systems that provide continuous, actionable insights into glucose levels without the need for routine fingersticks. The company’s flagship DexCom G6 and next-generation G7 systems, supported by integrated mobile applications and data platforms, enable improved glycemic control and patient engagement. It has established itself as a key innovator and market leader in CGM solutions, driving advancements in digital health and diabetes care.

MARKET RANKING

The Latin America blood glucose monitor market is characterized by the presence of established players, operating across healthcare systems with uneven reimbursement coverage, price sensitivity, and varying levels of technology adoption. Abbott Laboratories leads the regional market, driven by the increasing uptake of its FreeStyle Libre CGM systems, particularly in larger economies, such as Brazil, Mexico, and Argentina, supported by expanding private insurance coverage, affordability initiatives, and rising patient awareness. Dexcom has emerged as a major player in the CGM segment, with growing adoption of its advanced G6 and G7 platforms in specialist diabetes clinics and digitally enabled care settings. However, overall penetration remains constrained by limited reimbursement and high out-of-pocket costs in several countries. Medtronic maintains a solid presence through its MiniMed insulin pump systems and Guardian CGM sensors, with demand largely concentrated in advanced private healthcare settings focused on integrated and sensor-augmented diabetes management. Roche continues to hold a stable share across Latin America through its Accu-Chek SMBG portfolio, benefiting from strong physician trust, well-established distributor networks, and wide availability across hospital and retail pharmacy channels. Toward the value segment, Sinocare is gradually strengthening its footprint in select Latin American markets, leveraging cost-competitive SMBG devices and partnerships with local distributors to address price-sensitive, volume-driven demand at the lower end of the market.

Related Reports:

"Latin America Blood Glucose Monitor Market by Product (Blood Glucose Monitoring, Professional Point of Care), Application (Diabetes Management, Health & Wellness Monitoring), Test Site (Fingertip, Upper Arm), End User (Self/Homecare) - Forecast to 2030"

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com